Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
Brickell Biotech, Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, will report its Q2 2020 financial results on August 12, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Brickell Biotech, Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, will report its Q2 2020 financial results on August 12, 2020, after market close. Management will host a conference call at 4:30 PM ET to discuss financial results and corporate highlights. Brickell focuses on developing innovative therapeutics for skin diseases, including hyperhidrosis. The management team has extensive experience in product development, having worked on several successful products in the pharmaceutical and biotech industries.
Details
News Market Reaction – BBI
The recorded move for BBI in the trading session of this news was +1.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Wednesday, August 12, 2020. Brickell’s management will host a conference call and webcast at 4:30pm ET to discuss the financial results and recent corporate highlights.
To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13706625. To access the live webcast, please go to the investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.
About Brickell Bio
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.
Brickell Investor Contact:
IR@brickellbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.